Metastatic Castration-Resistant Prostate Cancer: Molecular Mechanisms and Novel Treatment Strategies
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 237
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue, entitled “Metastatic Castration-Resistant Prostate Cancer: Molecular Mechanisms and Novel Treatment Strategies”, aims to shed light on the groundbreaking research in the intricate and evolving field of metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a considerable challenge due to its heterogeneity, myriad drivers of progression, mechanisms of therapeutic resistance, and the emerging roles of epigenetics and cellular plasticity. We welcome submissions of original research and review articles that focus on novel systemic precision treatments, including those that target the currently ‘undruggable’, along with investigations into the influence of genetic and epigenetic alterations, the role of cellular plasticity in disease progression, immunotherapy, and targeted radiotherapy. Submissions delving into tumor microenvironment signaling and mechanisms of resistance to existing therapies are also encouraged. The aim of this Special Issue is to deepen our understanding of the complex mechanisms driving mCRPC, including the roles of epigenetics and cellular plasticity, and to spotlight innovative therapeutic strategies that improve patient outcomes and survival.
Dr. Christopher J. Ong
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic castration-resistant prostate cancer (mCRPC)
- molecular mechanisms
- novel treatment strategies
- systemic precision treatments
- epigenetics
- cellular plasticity
- tumor microenvironment signaling
- therapeutic resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
